PTO/SB/06a (08-03)
Approved for use through 07/51/2006, OMB 0691-0001
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no pers

INCODMATION DIGGS COURT	Filing Date
INFORMATION DISCLOSURE	First Named Inv
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1,99)	Art Unit
(Notice desimilation and of of it 1.33)	Examiner Name

Application Number	
Filing Date	
First Named Inventor	Ian Timothy William Matthews
Art Unit	
Examiner Name	
Attorney Docket Numb	er 065435-9033 US01

					U.S.	PATENTS				
Examiner Initial*	Examiner Cite No Patent Number Kind Codet Issue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		ant			
	1	6320063		2001-1	1-20	Denny et al.				
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Patentee or Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	to a	dd additional U.S. Publ			_	n information		d butto	on.	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	,	Kind Code4	Publication	Name of Patenter Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ţ5
	1	91/05824	wo			1991-05-02	National Research Development Corporation			
	2	00/05194	wo			2000-02-03	BTG International Limited			С
	3	03/078387	wo			2003-09-25	BTG International Limited			

Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit

(110110101011011011011011011011011011011			Examiner Na	ame	•			
				Attorney Docket Number		065435-9033 US01		
	4	2005/025537	wo		2005-03-24	BTG International Limited		_
If you wis	h to a	dd additional Foreig	n Patent Do	cument citatio	n information	please click the Add butt	on	_
			NON	I-PATENT LIT	ERATURE D	DCUMENTS		
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ite Initials* No (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T5		
	1	BERGE, S.M. et al.,	"Pharmaceu	itical Salts," J. P	harm. Sci. (197	7) 68(1):1-19		
	2					g 1,4-bls[[2-(dimethyl-amin Soc., Perkin Trans. (1999)		_
If you wis	h to a	dd additional non-pa	tent literatu	ire document c	itation informa	ation please click the Add	button	
				EXAMIN	ER SIGNATU	RE		
Examine	Signs	ature				Date Considered	1	_

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Not Order of USPTO Patent Documents at seas USBETO COUV or MEDE 901.04. * Enter of this flat issued the document. by the looks allow of the Secretary of the Secretary Course patent documents, the biolization of the year of the sign of the Emperor many provides the sendal results or other patent document. As a folization of the year of the sign of the Emperor many provides a result invalved or plant document. A folication of the Secretary of

Application Number Fling Date Fling Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Fling Total In an Timothy William Matthews Art Unit Fling Tota

CERTIFICATION STATEMENT

Please see 37 CFR 1.5	7 and 1.98 to	make the appropriate	selection(s	s)
-----------------------	---------------	----------------------	-------------	----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information discourse statement was known to any individual designated in 37 CFR 1.58(c) more than three months prior to the filling of the information disclosure statement See 37 CFR 1.57(c) and the contained in the contained in the information disclosure statement See 37 CFR 1.57(c) more than three months prior to the filling of the information disclosure statement See 37 CFR 1.57(c) more than three months prior to the filling of the information disclosure

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Charlene L. Yager

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature

Registration Number

48 887

lorin or the dignata			
Signature	Marlene & Ucique	Date (YYYY-MM-DD)	2006-08-10

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO is process) an application. Confidentially is governed by \$5 U.S. C. 122 and 3T CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, U.S. Operatment of Commence, P.O. Box 1456, Alexandrix, V.S. 2313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrix, V.S. 2313-1450.